The effects of a diet formulation with oats, soybeans, and flax on lipid profiles and uricemia in patients with AIDS and dyslipidemia.
BACKGROUND
Although the initiation of highly active antiretroviral therapy (HAART) is accompanied by an attenuation of viral load, metabolic disorders characterized by hyperglycemia, dyslipidemia, and lipodystrophy are often observed in patients under this treatment. Certain foods, such as oat bran, soy protein, and flaxseed, have been shown to improve a patient's lipid profile despite possible increases in uricemia. Thus, a bioactive compound was formulated using these foods to help patients with HIV/AIDS control metabolic disorders resulting from HAART.


METHODS
An uncontrolled before and after study was performed. The total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, and uric acid before and after 3 months of consuming the formulation were compared in patients. The compound was formulated such that 40g (the recommended daily intake) contained approximately 10g of flaxseed, 20g of oat bran, and 10g of textured soy protein.


RESULTS
The study population consisted of 139 patients, 31 of whom were included in the final analysis. There were no significant variations between the laboratory results obtained before and after consumption of the compound.


CONCLUSIONS
The regular consumption of the formulation together with individualized dietary guidance did not reduce lipid levels and did not contribute to an increase in uricemia in the study group. However, new studies with higher doses of the foods that compose the formulation should be encouraged to investigate whether these foods can positively influence the lipid profiles of these patients.
Programa de Pós-Graduação em Saúde e Desenvolvimento na Região Centro-Oeste, Universidade Federal do Mato Grosso do Sul, Campo GrandeMS.
Rosângela dos Santos
Rdos S
Ferreira
Residência em Clínica Médica, Faculdade de Medicina de São José do Rio Preto, São José do Rio PretoSP.
Daiane Colman
DC
Cassaro
Departamento de Clínica Médica, Faculdade de Medicina, Universidade Federal do Mato Grosso do Sul, Campo GrandeMS.
Hamilton
H
Domingos
Centro de Ciências Biológicas e da Saúde, Departamento de Tecnologia de Alimentos e Saúde Pública, Universidade Federal do Mato Grosso do Sul, Campo GrandeMS.
Elenir Rose Jardim Cury
ER
Pontes
Centro de Ciências Biológicas e da Saúde, Departamento de Tecnologia de Alimentos e Saúde Pública, Universidade Federal do Mato Grosso do Sul, Campo GrandeMS.
Priscila Hiane
PH
Aiko
Serviço de Nutrição, Hospital das Clínicas, Universidade Federal do Mato Grosso do Sul, Campo GrandeMS.
Júnia Elisa Carvalho de
JE
Meira
D000163:Acquired Immunodeficiency Syndrome / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D018554:Avena; D050171:Dyslipidemias / Q000139:chemically induced / Q000178:diet therapy*; D005260:Female; D019597:Flax; D005526:Food, Formulated; D006801:Humans; D008055:Lipids / Q000097:blood*; D008297:Male; D008875:Middle Aged; D013025:Glycine max; D016896:Treatment Outcome; D014527:Uric Acid / Q000097:blood*
D008055:Lipids; D014527:Uric Acid